- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00962780
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
2014년 11월 13일 업데이트: Pfizer
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a pneumococcal vaccine.
All subjects will receive 3 doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with each dose given approximately 1 month apart.
연구 개요
상태
완전한
연구 유형
중재적
등록 (실제)
303
단계
- 3단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Bloemfontein, 남아프리카, 9301
- Pfizer Investigational Site
-
Paarl, 남아프리카, 7626
- Pfizer Investigational Site
-
-
Gauteng
-
Johannesburg, Gauteng, 남아프리카, 2013
- Pfizer Investigational Site
-
Pretoria, Gauteng, 남아프리카, 0083
- Pfizer Investigational Site
-
Pretoria, Gauteng, 남아프리카, 0122
- Pfizer Investigational Site
-
Soweto, Gauteng, 남아프리카, 1818
- Pfizer Investigational Site
-
-
KwaZulu-Natal
-
Dundee, KwaZulu-Natal, 남아프리카, 3000
- Pfizer Investigational Site
-
-
Western Cape
-
Worcester, Western Cape, 남아프리카, 6850
- Pfizer Investigational Site
-
-
-
-
-
Bucuresti, 루마니아, 021105
- Pfizer Investigational Site
-
Bucuresti, 루마니아, 030303
- Pfizer Investigational Site
-
Constanta, 루마니아, 900709
- Pfizer Investigational Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
6년 이상 (어린이, 성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older
- Viral load < 50,000 copies/mL and CD4+ T cell count >= 200/uL within 6 months before study vaccination
- Receiving stable highly active antiretroviral therapy (HAART) or not currently receiving any antiretroviral therapy
- No previous vaccination with a pneumococcal vaccine
- Subject or parent/legal guardian able to complete an electronic diary
Exclusion Criteria:
- Acquired immune deficiency syndrome (AIDS) at time of enrollment
- Current illicit substance and/or alcohol abuse
- History of active chronic viral hepatitis
- Previous anaphylactic reaction to a vaccine or vaccine-related component
- Serious chronic disorders including metastatic malignancy and end-stage renal disease
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: 1
3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
|
13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants
기간: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results.
Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
|
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants
기간: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented.
GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated.
Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
|
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants
기간: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay.
GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated.
Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
|
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants
기간: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results.
Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
|
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants
기간: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results.
Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
|
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
기간: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented.
GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated.
Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws.
CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
|
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
기간: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results.
Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.
|
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
기간: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay.
GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated.
Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws.
CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
|
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
기간: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results.
Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.
|
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
|
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
기간: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented.
GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated.
Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws.
CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
|
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
기간: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results.
Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.
|
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
기간: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay.
GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated.
Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws.
CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
|
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
기간: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results.
Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.
|
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
|
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1
기간: Within 14 days after 13vPnC Dose 1
|
Specific local reactions were prompted for each day, and reported using an electronic diary.
Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to <12 years and 2.5 to 5.0 cm for participants aged greater than (>) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to <12 years and 5.1 to 10.0 cm for participants aged >12 years); Severe (>7 cm for participants aged 6 to <12 years and >10 cm for participants aged >12 years).
Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
Report of severe swelling was confirmed as data entry error.
|
Within 14 days after 13vPnC Dose 1
|
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2
기간: Within 14 days after 13vPnC Dose 2
|
Specific local reactions were prompted for each day, and reported using an electronic diary.
Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to <12 years and 2.5 to 5.0 cm for participants aged >12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to <12 years and 5.1 to 10.0 cm for participants aged >12 years); Severe (>7 cm for participants aged 6 to <12 years and >10 cm for participants aged >12 years).
Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
|
Within 14 days after 13vPnC Dose 2
|
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3
기간: Within 14 days after 13vPnC Dose 3
|
Specific local reactions were prompted for each day, and reported using an electronic diary.
Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to <12 years and 2.5 to 5.0 cm for participants aged >12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to <12 years and 5.1 to 10.0 cm for participants aged >12 years); Severe (>7 cm for participants aged 6 to <12 years and >10 cm for participants aged >12 years).
Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
|
Within 14 days after 13vPnC Dose 3
|
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1
기간: Within 14 days after 13vPnC Dose 1
|
Specific systemic events (fever >=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary.
Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity).
Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (>2 times in 24 hours); Severe (required intravenous hydration).
Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (>=6 loose stools in 24 hours).
All reporting of fever >40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.
|
Within 14 days after 13vPnC Dose 1
|
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2
기간: Within 14 days after 13vPnC Dose 2
|
Specific systemic events (fever >=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary.
Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity).
Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (>2 times in 24 hours); Severe (required intravenous hydration).
Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (>=6 loose stools in 24 hours).
All reporting of fever >40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.
|
Within 14 days after 13vPnC Dose 2
|
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3
기간: Within 14 days after 13vPnC Dose 3
|
Specific systemic events (fever >=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary.
Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity).
Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (>2 times in 24 hours); Severe (required intravenous hydration).
Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (>=6 loose stools in 24 hours).
All reporting of fever >40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.
|
Within 14 days after 13vPnC Dose 3
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2010년 3월 1일
기본 완료 (실제)
2013년 4월 1일
연구 완료 (실제)
2013년 4월 1일
연구 등록 날짜
최초 제출
2009년 8월 18일
QC 기준을 충족하는 최초 제출
2009년 8월 19일
처음 게시됨 (추정)
2009년 8월 20일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2014년 11월 17일
QC 기준을 충족하는 마지막 업데이트 제출
2014년 11월 13일
마지막으로 확인됨
2014년 11월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 6115A1-3002
- B1851021
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
Erasmus Medical Center아직 모집하지 않음
-
University of Maryland, BaltimoreNational Institute of Mental Health (NIMH); Albert Einstein College of Medicine; Yale University 그리고 다른 협력자들아직 모집하지 않음HIV 예방 | HIV 사전 노출 예방
-
Erasmus Medical Center모집하지 않고 적극적으로
13-valent Pneumococcal Conjugate Vaccine (13vPnC)에 대한 임상 시험
-
PATHUniversity College, London; FHI 360; Medical Research Council Unit, The Gambia; Serum Institute...완전한